Drotrecogin alfa (activated) for nonmenstrual toxic shock syndrome associated with methicillin resistant Staphylococcus aureus infection.
Nonmenstrual toxic shock syndrome (TSS) due to Staphylococcus aureus can lead to significant morbidity and mortality. While drotrecogin alfa (DA) has been employed in patients with Methicillin-resistant Staphylococcus aureus (MRSA) severe sepsis and septic shock, its utility in TSS remains unclear. The authors report a case of severe sepsis in the setting of MRSA-associated TSS that responded to treatment with DA. This case illustrates a potential role for DA in the treatment of toxic shock syndromes and emphasizes the importance of aggressive diagnostic and therapeutic modalities in approaching these conditions.
Haddadin
Dafer W
DW
Department of Internal Medicine, Division of Infectious Diseases, East Tennessee State University, Box 70622, Johnson City, TN 37614, USA. alhaddad@mail.etsu.edu
Samnani
Imran Q
IQ
Moorman
Jonathan P
JP
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D003873:Dermatitis, Exfoliative / Q000382:microbiology; D005260:Female; D059685:Herniorrhaphy; D006801:Humans; D016106:Methicillin Resistance; D008875:Middle Aged; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012121:Respiration, Artificial; D012772:Shock, Septic / Q000188:drug therapy* / Q000382:microbiology* / Q000628:therapy; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013526:Surgical Mesh; D013530:Surgical Wound Infection / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated